NextGen Mobile Solutions vs ASCCP Management Guidelines

NextGen® Mobile drives clinical efficiencies for providers, so they can regain time to focus on what matters. The NextGen Mobile platform serves as a mobile extension of the EHR, streamlining key clinical tasks, and helping providers more easily capture clinically relevant documentation. NextGen Mobile helps physicians see more patients, close encounters faster, and leave the office on time. Mobile workflow: Eliminate the hassle of logging into your practice management (PM) or EHR for key patient information. From your mobile device, you can: -See your clinical schedule -View key clinical content -Securely communicate with your team and colleagues outside your clinic -Capture charges and images from your mobile device and insert directly into the EHR -Capture diagnosis codes on the go, powered by IMO® Problem IT Terminology Mobile documentation: Improve provider productivity with mobile documentation. Dictate patient encounters, any time and from anywhere, and the information will return directly to the EHR fields.

The ASCCP Risk-Based Management Consensus Guidelines provide evidence-based recommendations for managing abnormal cervical cancer screening results and cancer precursors, including post-colposcopy and post-treatment scenarios. ASCCP is pleased to offer this app to streamline navigation of the ASCCP Risk-Based Management Consensus Guidelines for abnormal cervical cancer screening tests and cancer precursors. The guidelines articles, as published in the Journal of Lower Genital Tract Disease, as well as the comprehensive risk estimates, can be accessed through https://www.asccp.org/guidelines. These evidence-based management guidelines, initially developed in 2019, came together through a consensus process of 19 organizations. The updated management guidelines aim to: • Allow for a more complete and precise estimation of risk • Provide more appropriate intervention for high-risk individuals (detect and treat more precancer) • Recommend less intervention for low-risk individuals (decrease testing and treatment that won’t prevent cancer and may cause reproductive harm) • Allow for the future addition of new risk modifiers and screening and management technologies See https://www.asccp.org/UserGuide for tips on using the app.